AIOSYN
9.5.2023 11:03:35 CEST | Business Wire | Press release
Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics. With the AIRAT project, the three organizations will join forces to introduce CE-marked deep learning algorithms for automated mitosis detection to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005736/en/
Mitotic figures (cells that are in the process of dividing) are identified and highlighted with Aiosyn's algorithm for automated mitosis detection. (Photo: Business Wire)
Wouter Bulten, Chief innovation officer of Aiosyn: “At Aiosyn, we recognize the critical role pathologists play in diagnostics. Through close collaboration, this EFRO grant enables us to further develop AI tools that support pathologists and enhance pathology practice.”
Close to 20 million patients are diagnosed with cancer every year1. Unfortunately, incidence is expected to increase in the upcoming decades, with a predicted global burden of about 30 million new cancer cases per year by 20402. This underlines the need for new tools to improve the efficiency and accuracy of the disease diagnosis and treatment.
As part of this project, Aiosyn will further develop and validate AI-powered algorithms for breast and skin cancer diagnosis. One of such algorithms is Aiosyn’s solution for automated mitosis detection. The quantification of mitotic figures in cancer tissue is an essential part of the diagnosis of multiple tumor types. By leveraging AI-based digital biomarkers, pathologists can more accurately predict tumor growth and understand patient prognosis. This will help reduce observer variability, improve the accuracy and consistency of diagnoses, and ultimately enhance patient outcomes.
Jeroen van der Laak, professor at Radboud university medical center and CSO of Aiosyn: “Once you have decided which problem to solve, and have collected all required data, developing AI for Pathology is doable. But collecting high-quality data is tough, and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”
Aiosyn’s algorithms will be fully integrated in existing digital pathology workflows such as Sectra. The AI-powered solutions will aim to provide major progress in the assessment and disease management of cancer patients worldwide.
“We are excited to partner with Aiosyn and Radboud UMC on this project," said Matthijs van Oosterhout, on behalf of Pathologie-DNA, chairman of Pathologie-DNA B.V. "Together, we can leverage our respective strengths to develop AI solutions that will improve patient outcomes and advance the field of pathology. This collaboration is a great example of how start-ups and established companies can work together to drive innovation."
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice.
About Radboud university medical center
Radboud university medical center is a university medical center for patient care, research, and education, located in Nijmegen. We mainly concentrate on prevention, meaningful and prudent healthcare, sustainability, artificial intelligence and data-driven systems, the molecular mechanisms of diseases and new treatments, and training the professionals of tomorrow.
About Pathologie-DNA
Pathologie-DNA is a collaboration between three pathology laboratories Jeroen Bosch Ziekenhuis, located in ‘s-Hertogenbosch, St. Antonius Ziekenhuis located in Nieuwegein and Rijnstate located in Arnhem. Pathologie-DNA is the partner in pathology for medical specialists, general practitioners and private diagnostic centres. We work with digital pathology. This makes it possible to provide continuous high-quality diagnostics. Consultation between colleagues and consultation with academic hospitals guarantee this quality.
Sources
1. World Cancer Day 2023: Close the care gap - PAHO/WHO | Pan American Health Organization
2. World Cancer Report: Cancer Research for Cancer Prevention (who.int)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005736/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom